NVCT News and Press, Nuvectis Pharma Inc.

2024-06-13 14:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-28 06:10:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny biotech stocks. Developing therapeutics to cure diseases ...

2024-05-23 00:34:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2024-05-16 10:14:46 ET Summary Nuvectis Pharma, Inc. is an oncology-focused biopharma with two drugs in early-stage clinical trials. Their most advanced project, NXP800, has shown some very early activity in patients with ARID1A-mutated ovarian cancer. Nuvectis Pharma faces ca...

2024-05-07 10:35:46 ET More on Nuvectis Pharma Seeking Alpha’s Quant Rating on Nuvectis Pharma Historical earnings data for Nuvectis Pharma Financial information for Nuvectis Pharma Read the full article on Seeking Alpha For further details see...

Encouraging preliminary data announced from the NXP800 Phase 1b study in platinum resistant, ARID1a-mutated ovarian cancer, a program granted Fast Track Designation by the US FDA Data presented at the 2024 AACR demonstrate NXP900's robust activity in non-small cell cancer cell lines Sev...

Highly Synergistic Antiproliferative Activity in EGFR-resistant Cells in Combination with Osimertinib, the Active Ingredient in Tagrisso TM Single Agent Antiproliferative Activity in Cells Resistant to Alectinib, the Active Ingredient in Alecensa TM Fort Lee, NJ, April 08,...

2024-03-24 15:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, t...

FORT LEE, NJ, March 15, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (“Nuvectis”, “Company”), a biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today ann...